Strides Shasun receives US FDA approval for memantine HCl tabletsStrides Shasun receives US FDA approval for memantine HCl tablets

According to IMS data, the US market for memantine hydrochloride tablets USP, 5 mg and 10 mg is approximately US$ 60 million. The product will be manufactured at the company’s flagship facility at Bengaluru and marketed by Strides Pharma Inc in the US market. The product will be launched immediately.

Memantine hydrochloride tablets are indicated for the treatment of moderate to severe Alzheimer-type dementia.

Strides Shasun is a vertically integrated global pharmaceutical company headquartered in Bengaluru. The company has four business verticals, viz., regulated markets, emerging markets, institutional business and active pharmaceutical ingredients. 

Strides shasun, us fda, memantine hcl tablets